RO 7033877

Drug Profile

RO 7033877

Alternative Names: RO 7033877

Latest Information Update: 22 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 22 Apr 2016 Phase-I development is ongoing in USA and Netherlands
  • 01 Jul 2014 Roche initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT02165332)
  • 30 Jun 2014 Phase-I clinical trials in Healthy volunteers in Netherlands (IV) (NCT02156323)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top